Maturitas最新文献

{"title":"Hearing changes and trajectories during the menopausal transition and their association with metabolic factors.","authors":"Yoonyoung Jang, Yoosoo Chang, Jieun Lee, Byungtae Seo, Yoosun Cho, Minjeong Kim, Jae Ho Park, Jeonggyu Kang, Ria Kwon, Ga-Young Lim, Kye-Hyun Kim, Hoon Kim, Yun Soo Hong, Jihwan Park, Di Zhao, Juhee Cho, Eliseo Guallar, Seungho Ryu","doi":"10.1016/j.maturitas.2025.108686","DOIUrl":"10.1016/j.maturitas.2025.108686","url":null,"abstract":"<p><strong>Background: </strong>Hearing loss is an emerging public health concern, with women typically experiencing deterioration during menopause; however, longitudinal studies across this transition are limited. This study examined hearing changes across the menopausal transition in order to identify distinct patterns of hearing decline from 11 years before to 9 years after the final menstrual period, with the goal of informing strategies for early detection and intervention.</p><p><strong>Materials and methods: </strong>We followed 4448 women aged 42-52 years who underwent regular health exams at the Kangbuk Samsung Hospital Total Healthcare Centers (2014-2018) through 2023. Hearing changes were analyzed using linear mixed-effects models across the menopausal transition. Group-based trajectory modeling was applied to assess heterogeneity in hearing deterioration relative to the final menstrual period.</p><p><strong>Results: </strong>A significant change in average bilateral hearing thresholds was observed across menopausal transition. Hearing change during the menopausal transition varied by obesity, with minimal change in those with obesity and slight improvement in those without during early transition. Group-based trajectory modeling identified two patterns: Group 1 (71.7 %) had stable hearing until the final menstrual period, then declined; Group 2 (28.3 %) showed poorer baseline hearing with a steeper, persistent decline. At baseline, Group 2 exhibited a significantly higher prevalence of overweight/obesity and hyperglycemia than Group 1.</p><p><strong>Conclusions: </strong>Postmenopausal stages were associated with significant hearing decline in middle-aged women. Furthermore, subgroups with metabolically unhealthy profiles exhibited poorer baseline hearing and a steeper decline in hearing, highlighting the need for appropriate screening and management during the menopausal transition.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"201 ","pages":"108686"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reproductive milestones, use of menopausal hormone therapy, and risk of hearing loss: A life course study of 214 327 women.","authors":"Chunying Fu, Qi Wang, Wenting Hao, Salim S Virani, Claudia Barth, Dongshan Zhu","doi":"10.1016/j.maturitas.2025.108685","DOIUrl":"10.1016/j.maturitas.2025.108685","url":null,"abstract":"<p><strong>Objectives: </strong>The associations between female reproductive milestones, use of menopausal hormone therapy (MHT), and the risk of hearing loss remain unclear. This study explored these associations and the potential mediating pathways.</p><p><strong>Methods: </strong>This longitudinal study used data from the UK Biobank. The sample comprised 214,327 women aged 40-69 years without hearing loss at baseline and without diagnosis of the condition in the first five years of follow-up. Adjusted Cox proportional hazard models were used, along with sensitivity analyses, assessments of dose-response relationships, and joint effect analyses. The mediating roles of cardiovascular disease (CVD) and diabetes were also investigated.</p><p><strong>Results: </strong>Over a mean follow-up of 13.42 years, 5106 women developed hearing loss. Higher parity (≥4 children; HR 1.29, 95 % CI 1.14-1.46), premature menopause (<40 years; 1.27, 1.14-1.41), both shorter (≤30 years; 1.12, 1.02-1.22) and longer (≥45 years; 1.16, 1.01-1.32) reproductive lifespans were associated with an increased risk of hearing loss. Surgical menopause (2.71, 2.39-3.07) and natural menopause (2.49, 2.25-2.75) showed higher risk compared with pre-menopause. MHT use was associated with increased risk of hearing loss in women with typical-age natural menopause, but not in those with premature or late menopause (although point estimates were above 1 the 95 % CI included 1). CVD mediated 46.07 % of the association between parity and hearing loss, and 19.61 % of the association between early menopause and hearing loss.</p><p><strong>Conclusion: </strong>Reproductive factors (such as parity and age at menopause) may influence the risk of hearing loss in women. These findings suggest that reproductive history should be incorporated into hearing health assessments, and integrated health strategies addressing both reproductive and metabolic health may help mitigate the risk of hearing loss in women.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"201 ","pages":"108685"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spirometric patterns associated with the progression of cardiometabolic diseases in middle-aged and older adults: A prospective cohort study.","authors":"Nana Wang, Xuezhong Shi, Tianrun Wang, Xiaocan Jia, Zhixing Fan, Chaojun Yang, Yuping Wang, Jingwen Fan, Chenyu Zhao, Yali Niu, Yongli Yang","doi":"10.1016/j.maturitas.2025.108689","DOIUrl":"10.1016/j.maturitas.2025.108689","url":null,"abstract":"<p><strong>Objective: </strong>To explore the associations between spirometric patterns and cardiometabolic diseases progression in middle-aged and older adults, and examine the mediating effects of levels of C-reactive protein and score on the atherogenic index of plasma.</p><p><strong>Methods: </strong>Based on 320,795 participants from the UK Biobank, five spirometric patterns were defined using baseline measurements of forced expiratory volume in one second and forced vital capacity. The cardiometabolic diseases included type 2 diabetes, coronary heart disease, and stroke. Multistate model and mediation analysis were used for statistical analyses.</p><p><strong>Results: </strong>During a median follow-up of 13.68 years, 37,053 participants developed at least one cardiometabolic disease, 3746 developed cardiometabolic multimorbidity, and 22,204 died. In the transition from baseline to first cardiometabolic diagnosis, the hazard ratios (95 % confidence intervals) compared with normal lung function were 1.14 (1.11, 1.17) for airflow obstruction, 1.17 (1.10, 1.23) for preserved ratio impaired spirometry alone, 1.21 (1.10, 1.32) for restrictive spirometric pattern alone, and 1.38 (1.33, 1.43) for the combined preserved ratio impaired spirometry with restrictive spirometric pattern. Combined preserved ratio impaired spirometry with restrictive spirometric pattern was also associated with a higher risk of progressing from first cardiometabolic disease to multimorbidity (hazard ratio: 1.21; 95 % confidence interval: 1.10, 1.33). The levels of C-reactive protein and score on the atherogenic index of plasma mediated 6.56 % to 15.74 % of the associations between spirometric patterns and cardiometabolic diseases.</p><p><strong>Conclusions: </strong>Spirometric patterns exhibit differential effects throughout the progression of cardiometabolic diseases, and C-reactive protein and atherogenic index of plasma play a partial role in mediating these effects.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"201 ","pages":"108689"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy and improve sexual function in postmenopausal women: A 52-week long-term follow-up.","authors":"Hichem Bensmail, Fabienne Marchand Lamiraud, Carine Martin, Sofie Pelckmans, Firas Cha'ban, Aliette Siboni Frisch, Gulcan Deniz, Pascale Sabban Serfati, Brigitte Caubo, Brice Gurriet, Isabelle Petit Breuilh, Ann Inge Pastijn, Nicolas Berreni, Michel Cosson","doi":"10.1016/j.maturitas.2025.108687","DOIUrl":"10.1016/j.maturitas.2025.108687","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the long-term efficacy and safety of a single injection session of cross-linked hyaluronic acid for postmenopausal vulvovaginal atrophy.</p><p><strong>Study design: </strong>12-week, randomised, placebo-controlled, single-blind phase followed by 40-week open-label phase. At study start, patients received hyaluronic acid or placebo injection. At 12 weeks, patients who initially received placebo received hyaluronic acid.</p><p><strong>Main outcome measures: </strong>Mean change from baseline in the severity score of the most bothersome symptom, scores for vulvovaginal atrophy individual symptoms, score on the Female Sexual Function Index and vaginal pH after hyaluronic acid injection. Patients receiving hyaluronic acid were followed to 36 weeks or 52 weeks if treated at study start.</p><p><strong>Results: </strong>115 patients receiving hyaluronic acid were analysed. The mean score for most bothersome symptom and all individual symptom scores were significantly reduced from baseline at all time points (p < 0.001). The initial decrease in most bothersome symptom was observed at 4 weeks, with a mean (SD) decrease of -1.05 (1.05) to 1.69 (1.11), and maintained up to 52 weeks. Mean full-scale score on the Female Sexual Function Index was significantly increased from baseline at all time points (p < 0.001). The initial increase was observed at 4 weeks, with a mean increase of 4.50 (6.51) to 20.54 (8.60), and maintained up to 52 weeks. Improvement was observed across all domains of the Female Sexual Function Index. There was a general trend for improvement in vaginal pH.</p><p><strong>Conclusions: </strong>A single injection session of hyaluronic acid is effective in reducing vulvovaginal symptomatology and in improving sexual function for up to 52 weeks, making it a suitable management option for moderate to severe vulvovaginal atrophy symptoms.</p><p><strong>Clinical trials: </strong>gov identifier NCT04219722.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"201 ","pages":"108687"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of exercise on cardiovascular parameters in postmenopausal women: A narrative review.","authors":"Vitor E Valenti, Bruno M Candeloro, Rodrigo D Raimundo, Luana A Gonzaga, Luiz O C Jaloto, João L N Crippa, Douglas B O Assis, Lucas F Laurindo, Andrey A Porto, David M Garner, Beatriz S Pilão, Sandra Maria Barbalho","doi":"10.1016/j.maturitas.2025.108688","DOIUrl":"10.1016/j.maturitas.2025.108688","url":null,"abstract":"<p><strong>Introduction: </strong>Several studies indicate that regular physical activity can reduce systolic and diastolic blood pressure, improve endothelial function, and enhance overall cardiovascular fitness in postmenopausal women. To gain a deeper understanding, we conducted a narrative review of systematic reviews to assess the impact of exercise on cardiovascular parameters in postmenopausal women.</p><p><strong>Method: </strong>The literature search was conducted using the Excerpta Medica, Medical Literature Analysis and Retrieval System Online, Scopus, and Web of Science databases. We included systematic reviews investigating the effects of exercise on cardiovascular parameters in postmenopausal women, with publications considered up until December 2024.</p><p><strong>Results: </strong>Following the exclusion of 187 publications, three systematic reviews were selected. These reported significant exercise-induced improvements in vasomotor symptoms, systolic blood pressure, diastolic blood pressure and heart rate.</p><p><strong>Conclusion: </strong>This narrative review revealed that exercise benefits cardiovascular health in postmenopausal women. Still, methodological limitations emphasize the need for better systematic reviews. Clinicians ought to interpret findings carefully when recommending physical exercise.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"201 ","pages":"108688"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of and risk factors for female sexual dysfunction in middle-aged Vietnamese women: A cross-sectional hospital-based study.","authors":"Hoang-Phuong Nguyen, Lan T M Dao, Le Phuong Hoang Anh, Tan-Sinh Thi Nguyen, Shivena Rachel Chua Uy, Thi Ha Nguyen, Thanh Van Hoang, Thi Thanh Toan Do, Thanh Liem Nguyen","doi":"10.1016/j.maturitas.2025.108743","DOIUrl":"https://doi.org/10.1016/j.maturitas.2025.108743","url":null,"abstract":"<p><strong>Objectives: </strong>Female sexual dysfunction encompasses a variety of sexual issues that can impact a woman's sexual health and overall quality of life. This study assesses the prevalence and associated factors among Vietnamese women aged 40-50 at the Women's Health Center, Vinmec International General Hospital, Hanoi, Vietnam.</p><p><strong>Study design: </strong>A hospital-based cross-sectional study was conducted with 204 women aged 40-50 years who visited the Women's Health Center, Vinmec International General Hospital, between October 2023 and June 2024. This study adheres to the STROBE guideline.</p><p><strong>Main outcome measures: </strong>Participants completed a self-administered questionnaire covering medical and sexual histories, which included the validated Vietnamese versions of the Female Sexual Function Index and the Depression, Anxiety, and Stress Scale-21.</p><p><strong>Results: </strong>The prevalence of sexual dysfunction was 45.1 %. The prevalence of stress was 31.4 %, anxiety 43.1 %, and depression 26.0 %. Six factors were associated with female sexual dysfunction: lower levels of education, skilled occupation, late bedtime, no or infrequent physical activity, low monthly average income, and no or infrequent communication of sexual desires to a partner.</p><p><strong>Conclusion: </strong>The study suggests a high prevalence of female sexual dysfunction among Vietnamese women and identifies its associated risk factors. These results can serve as a practical reference for future screening and prevention efforts to address female sexual dysfunction in Vietnam.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"202 ","pages":"108743"},"PeriodicalIF":3.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age at menopause and the progression of frailty among middle-aged and older women: A prospective cohort analysis from CHARLS.","authors":"Xinyue Zhang, Wei Yu, Yueqin Zhu, Runfei Zhang, Yuhua Zhang","doi":"10.1016/j.maturitas.2025.108742","DOIUrl":"https://doi.org/10.1016/j.maturitas.2025.108742","url":null,"abstract":"<p><strong>Objective: </strong>Menopause marks an important transition in women's health, with the age at menopause influencing a variety of later-life health risks. However, the impact of menopause timing on longitudinal progression of frailty among Chinese middle-aged and older women remains unclear.</p><p><strong>Methods: </strong>We conducted a prospective cohort study using data from the China Health and Retirement Longitudinal Study from 2011 to 2018. A total of 11,984 women aged 45 years and older who experienced natural menopause were included. Frailty index was calculated using 30 health deficits encompassing physical, cognitive, and psychological domains. Age at menopause was categorized as <40, 40-44, 45-49, 50-55, and > 55 years. Mixed-effects linear regression models were used to examine the association between age at menopause and frailty progression, adjusting for sociodemographic, lifestyle, and health-related confounders.</p><p><strong>Results: </strong>Women who experienced menopause after age 55 exhibited the fastest frailty progression compared with those with menopause at age 50-55 (fully adjusted β = 0.43; 95 % confidence interval, 0.05 to 0.81; P = 0.027). Women who underwent menopause at ages 40-44 also had a significantly accelerated frailty progression (β = 0.35; 95 % confidence interval, 0.07 to 0.64; P = 0.016). In contrast, premature ovarian insufficiency (<40 years) was associated with lower baseline frailty index and a slower progression of frailty during follow-up.</p><p><strong>Conclusions: </strong>Both early and late menopause are associated with accelerated frailty progression among Chinese middle-aged and older women. These findings highlight the need for early identification and targeted preventative interventions in women at risk of atypical menopause timing to promote healthy aging.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"202 ","pages":"108742"},"PeriodicalIF":3.6,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microablative and non-ablative laser and radiofrequency treatment of genitourinary syndrome of menopause: A randomised controlled trial with four different energies.","authors":"Helena Slongo, Dulce C P Henriques, Alexandra P N Ongaratto, Helymar C Machado, Renata M Triglia, Cássia R T Juliato","doi":"10.1016/j.maturitas.2025.108737","DOIUrl":"https://doi.org/10.1016/j.maturitas.2025.108737","url":null,"abstract":"<p><strong>Objective: </strong>This study compared the effects of four different types of energy treatments on women with genitourinary syndrome of menopause.</p><p><strong>Material and methods: </strong>Four-arm single-blind randomised clinical trial, with 48 postmenopausal women with genitourinary syndrome of menopause. Participants were randomised into four groups: Group 1 received sessions of non-ablative Er:YAG laser; Group 2 received sessions of microablative CO2 laser; Group 3 underwent sessions of non-ablative radiofrequency; and Group 4 received sessions of fractional microablative radiofrequency. The primary outcome was the assessment of symptoms of genitourinary syndrome of menopause correlated with vaginal histological analysis at baseline and 1 month after the end of treatment. Secondary outcomes included sexual function and urinary symptoms, treatment satisfaction and major adverse events.</p><p><strong>Results: </strong>All treatment modalities demonstrated significant improvement in dryness (p < 0.001) and dyspareunia (p < 0.001) measured by visual analogue scales and in vaginal symptoms assessed with the International Consultation on Incontinence Questionnaire-Vaginal Symptoms (p < 0.001), with no significant differences between groups. All treatment energies resulted in significant increases in tissue thickness (p < 0.001), layer number (p < 0.001), and collagen quantity and depth (p < 0.001), with no significant difference among the groups.</p><p><strong>Conclusions: </strong>Both microablative and non-ablative energies, whether utilizing laser or radiofrequency, are effective treatments for the symptoms of genitourinary syndrome of menopause, with histological correlations observed and no notable differences in efficacy between modalities.</p><p><strong>Clinical trial registration: </strong>Registered in REBEC (Registro Brasileiro de Ensaios Clínicos; Brazilian Registry of Clinical Trials). Trial registration number RBR-5vw3vpg. The protocol can be accessed at https://ensaiosclinicos.gov.br/rg/RBR-5vw3vpg.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"202 ","pages":"108737"},"PeriodicalIF":3.6,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ubiquitous monitoring of the environment and menopause.","authors":"Y Celik, A Godfrey","doi":"10.1016/j.maturitas.2025.108729","DOIUrl":"https://doi.org/10.1016/j.maturitas.2025.108729","url":null,"abstract":"","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":" ","pages":"108729"},"PeriodicalIF":3.6,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are health-related, lifestyle, work-related, and socio-demographic factors associated with work productivity among menopausal women? A systematic review.","authors":"Michelle G A Clevis, Karen Nieuwenhuijsen, Irene G M van Valkengoed, Teddy Oosterhuis, Karin I Proper, Sandra H van Oostrom","doi":"10.1016/j.maturitas.2025.108646","DOIUrl":"10.1016/j.maturitas.2025.108646","url":null,"abstract":"<p><p>An increasing number of women of menopausal age, many of whom experience menopausal symptoms, are participating in the workforce. Understanding the factors that influence work productivity in this life stage can inform the development of targeted interventions. This systematic review explores which health-related, lifestyle, work-related, and socio-demographic factors are associated with work productivity among menopausal women. A systematic search was conducted for observational studies in PubMed, PsycINFO, and Embase up to July 2024. The risk of bias was assessed using an adapted Newcastle-Ottawa scale. The GRADE framework for prognostic research was applied to evaluate the quality of evidence. A total of 29 studies were included. Menopausal symptoms in general, as well as psychological and vasomotor symptoms, and lower sleep quality were associated with lower at-work productivity, with moderate to high quality of evidence. Additionally, there was moderate quality of evidence that better (perceived) health was associated with higher at-work productivity. Regarding absenteeism, moderate evidence was found for an association with vasomotor symptoms. Inconclusive evidence was found for socio-demographic, work-related factors and remaining health-related and lifestyle factors in relation to both at-work productivity and absenteeism. This review highlights the association of menopausal symptoms and poor sleep quality with decreased work productivity in menopausal women. The evidence for other associations was limited due to the low quality of available evidence or a lack of studies. Further research on modifiable lifestyle and work-related factors is needed to improve the work functioning of women during menopause.</p>","PeriodicalId":94131,"journal":{"name":"Maturitas","volume":"200 ","pages":"108646"},"PeriodicalIF":3.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}